Patient characteristics
| Characteristic . | Quantity . |
|---|---|
| Overall | |
| Enrolled, no./evaluable, no. | 24/19 |
| Median age, y (range) | 13 (2-21) |
| Male, no./female, no. | 12/12 |
| APL cohort | |
| Enrolled, no./evaluable, no. | 14/13 |
| Median age, y (range) | 17 (4-21) |
| Male, no./female, no. | 8/6 |
| Dose level: 0.15 mg/kg | |
| First relapse, no. patients | 13 |
| Second or subsequent relapse, no. patients | 1 |
| Dose escalation (non-APL) cohort | |
| Enrolled, no./evaluable, no. | 10/6 |
| Median age, y (range) | 9.5 (2-17) |
| Male, no./female, no. | 4/6 |
| Dose level: 0.15 mg/kg | |
| ALL, no. patients | 3 |
| AML, no. patients | 1 |
| Dose level: 0.2 mg/kg | |
| ALL, no. patients | 2 |
| AML, no. patients | 3 |
| B-cell lymphoma, no. patients | 1 |
| Characteristic . | Quantity . |
|---|---|
| Overall | |
| Enrolled, no./evaluable, no. | 24/19 |
| Median age, y (range) | 13 (2-21) |
| Male, no./female, no. | 12/12 |
| APL cohort | |
| Enrolled, no./evaluable, no. | 14/13 |
| Median age, y (range) | 17 (4-21) |
| Male, no./female, no. | 8/6 |
| Dose level: 0.15 mg/kg | |
| First relapse, no. patients | 13 |
| Second or subsequent relapse, no. patients | 1 |
| Dose escalation (non-APL) cohort | |
| Enrolled, no./evaluable, no. | 10/6 |
| Median age, y (range) | 9.5 (2-17) |
| Male, no./female, no. | 4/6 |
| Dose level: 0.15 mg/kg | |
| ALL, no. patients | 3 |
| AML, no. patients | 1 |
| Dose level: 0.2 mg/kg | |
| ALL, no. patients | 2 |
| AML, no. patients | 3 |
| B-cell lymphoma, no. patients | 1 |